Literature DB >> 10694950

Eosinophil ablation and tumor development.

D T Wong1, S M Bowen, A Elovic, G T Gallagher, P F Weller.   

Abstract

Tissue eosinophilia in squamous cell carcinoma has long been recognized; however, the role of eosinophils in tumor development remains unclear. Studies have reported both favorable and unfavorable prognoses for patients with tumors exhibiting tumor-associated tissue eosinophilia (TATE). This study seeks to elucidate the potential role of the eosinophil in squamous cell carcinoma development and provide an experimental model for future studies. The carcinogen-induced hamster oral cancer model was found to fulfill these objectives. Eosinophils progressively infiltrate into this carcinogen-induced oral cancer model. We now demonstrate that TATE is completely abolished by the use of an anti-interleukin-5 monoclonal antibody (mAb) preparation, TRFK-5. Clinical observations revealed that TRFK-5-treated hamsters exhibited smaller tumor burden and delayed onset of tumor development. The results suggest that anti-interleukin-5 antibody treatment may delay and/or inhibit tumor development, and that eosinophils may have a tumor-promoting role.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10694950     DOI: 10.1016/s1368-8375(99)00023-8

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  24 in total

1.  Eosinophils in health and disease: the LIAR hypothesis.

Authors:  J J Lee; E A Jacobsen; M P McGarry; R P Schleimer; N A Lee
Journal:  Clin Exp Allergy       Date:  2010-04       Impact factor: 5.018

Review 2.  Eosinophils in innate immunity: an evolving story.

Authors:  Revital Shamri; Jason J Xenakis; Lisa A Spencer
Journal:  Cell Tissue Res       Date:  2010-11-03       Impact factor: 5.249

Review 3.  Therapeutic strategies for harnessing human eosinophils in allergic inflammation, hypereosinophilic disorders, and cancer.

Authors:  Zhaleh J Amini-Vaughan; Margarita Martinez-Moczygemba; David P Huston
Journal:  Curr Allergy Asthma Rep       Date:  2012-10       Impact factor: 4.806

Review 4.  The expanding role(s) of eosinophils in health and disease.

Authors:  Elizabeth A Jacobsen; Richard A Helmers; James J Lee; Nancy A Lee
Journal:  Blood       Date:  2012-08-30       Impact factor: 22.113

5.  Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion.

Authors:  Georgios T Stathopoulos; Taylor P Sherrill; Sophia P Karabela; Kasia Goleniewska; Ioannis Kalomenidis; Charis Roussos; Barbara Fingleton; Fiona E Yull; R Stokes Peebles; Timothy S Blackwell
Journal:  Am J Respir Crit Care Med       Date:  2010-07-01       Impact factor: 21.405

6.  Tumour-Associated Tissue Eosinophilia in Oral Squamous Cell Carcinoma- A Boon or a Bane?

Authors:  Shweta Yellapurkar; Srikant Natarajan; Karen Boaz; Mohan Baliga; Premalatha Shetty; Nidhi Manaktala; Mukul Prasad; Mahalakshmi Ravi
Journal:  J Clin Diagn Res       Date:  2016-04-01

7.  Quantitative Evaluation of Tumour--Associated Tissue Eosinophilia and Cyclo-oxegenase-2 Gene in Oral Cancer Patients with Assessment of Long Term Outcomes.

Authors:  N Rakesh; Asha Iyengar; Kuhu Majumdar; G S Vidya; S S Shantha Kumar
Journal:  Pathol Oncol Res       Date:  2015-11-17       Impact factor: 3.201

8.  Interleukin-2 immunotherapy action on innate immunity cells in peripheral blood and tumoral tissue of pancreatic adenocarcinoma patients.

Authors:  Luca Degrate; Cinzia Nobili; Claudio Franciosi; Roberto Caprotti; Fernando Brivio; Fabrizio Romano; Biagio Eugenio Leone; Rosangela Trezzi; Franco Uggeri
Journal:  Langenbecks Arch Surg       Date:  2008-08-01       Impact factor: 3.445

9.  Increased blood clotting, microvascular density, and inflammation in eotaxin-secreting tumors implanted into mice.

Authors:  Michael Samoszuk; Tom Deng; Mark J Hamamura; Min-Ying Su; Nicholas Asbrock; Orhan Nalcioglu
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

10.  Eosinophils and oral squamous cell carcinoma: a short review.

Authors:  C P Martinelli-Kläy; B R R N Mendis; T Lombardi
Journal:  J Oncol       Date:  2009-12-16       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.